Media stories about Pain Therapeutics (NASDAQ:PTIE) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pain Therapeutics earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.0964509083622 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Global Pain Management Therapeutics Market Key Players: Merck & Co., Pfizer, Purdue Pharma LP (journalhealthcare.com)
- Drug Marketing and Advertising Under Fire (pharmexec.com)
- Pain Management Therapeutics Market will Become Worth US$ 88253.4 Million by the End of 2025 (newspharmaceuticals.com)
- Global Topical Pain Management Therapeutics in Sports Medicine Market Assessment and Key Insights Analyzed till … (journalhealthcare.com)
- Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the … (prnewswire.com)
A number of equities analysts have issued reports on the company. ValuEngine cut Pain Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research upgraded Pain Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a report on Wednesday, March 14th.
Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter. sell-side analysts expect that Pain Therapeutics will post -1.65 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3343870/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-pain-therapeutics-ptie-share-price-2.html.
About Pain Therapeutics
Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.